about
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesEmerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases.Current status of immunotherapy for non-small-cell lung cancer.Fertility drugs, reproductive strategies and ovarian cancer risk.Breast cancer metastatic to the pituitary gland: a case reportAfatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?Cysts of the canal of Nuck: ultrasound and magnetic resonance imaging findings.Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.Emerging role of cetuximab in the treatment of colorectal cancer.Chemotherapy and target therapy in the management of adult high- grade gliomas.Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.Clinical use of fertility agents and risk of breast cancer: a recent update for an old problem.Correlation between fertility drugs use and malignant melanoma incidence: the state of the art.Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.Diagnosis and management of typical and atypical lung carcinoids.Treatment of lung large cell neuroendocrine carcinoma.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.Update on medical treatment of small intestinal neuroendocrine tumors.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.FNA and CNB in the diagnosis of pulmonary lesions: a single-center experience on 665 patients, comparison between two periods.Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report.Circulating tumor cells in high-risk nonmetastatic colorectal cancer.Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?Cognitive impairment and chemotherapy: a brief overview.Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yet.Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access programIs CEA better than CYFRA 21-1 in the monitoring of squamous cell lung cancer progression?Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective StudyCharacterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapySomatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs
P50
Q26750748-ADF253AD-A28C-4ED7-B88A-F1A7B90B7FF4Q26849477-D0C76D8D-699C-4785-95BD-D326C4E5649AQ30234436-69F5BB94-17AB-44B6-A7F3-F3E4ABCB524BQ30248865-E32DB261-C673-4F20-94AA-3F923DFD3A64Q33608317-9D0B9A83-3805-475B-B89D-173AC7E34006Q36235948-B665B73A-4652-4505-BAB9-41BCEBFEE903Q36594244-59905279-76DB-4AC7-A89C-D00540C12E1DQ36595710-1C17A41E-3A03-4BF4-B168-D0288E78C726Q37321114-6F4C9EBA-2284-4B5D-BD4D-7189EF328DBCQ37977525-1E07178D-89AE-4B8A-9215-0969D6E4F1DCQ38029398-385114D8-75C2-4976-9B59-8DBF5702C13CQ38176601-10514A32-D515-4D60-A60C-A574AC49D3DFQ38203882-23679A80-1035-4D11-ADFE-7D7308057844Q38206084-A1352E56-3CD9-4EF2-BCA2-F9D1A5D6ADFAQ38223603-7D8180DF-C10B-43F9-AA28-98C537EE6B1BQ38232753-F6C7AF68-E6D6-461F-883F-F4F400AD4374Q38611252-810B1350-2AA0-40F8-B87D-A0CEAE72791CQ38657676-461BAABB-3972-48BA-973F-33E92648F507Q38751034-7FAD56D0-112E-4060-9B2D-2834EDE8B720Q38760870-A2A37EE6-EA48-4307-9AC1-832B948CCC35Q38763111-718CC6DD-3A1E-4543-A8B4-30A9A96F0FC6Q38823755-279467D3-BB66-4C01-A1E9-761D2D512E23Q38879904-50A032F4-BC73-4FCB-B58C-CA118A1B7F8CQ38909078-BC761783-818A-4B82-B9B8-A356156FC801Q38916160-33F17BE9-5F5F-4522-95C7-F788F2065E41Q39201601-545DF2E2-6FDA-4C5E-B1FE-FBCE716101E7Q40212364-96852E22-8703-41F6-BC95-D38BCBEA3946Q41236564-C9F5B645-9DD9-42F5-87C3-35D546A42781Q43106936-33FDE979-8728-4804-8830-34F563ED5433Q46332622-D3550D4F-8303-4EA3-94D3-6B2355F96750Q46444002-16BDAD24-9510-40C4-BA91-CC9554694602Q47691798-97D2AED6-58E2-4323-902F-92756E110DF8Q47841017-952F1C8F-C79D-456D-A910-13BB4B8CF5F7Q50919710-4212FD12-70C2-48F2-A7B7-AE19DE5E6FAFQ62661812-56851500-1465-4B26-AD50-140339AAA13DQ83254496-7E324FB8-FB2F-4CAD-BDFF-E7AEF67E5A35Q90928599-E79027D8-C327-4570-82C7-A9A32A916EC8Q92142291-EAD83C9D-5727-4193-B291-0AE60D2A89ECQ92691043-F70F4F52-0A0D-4AE1-9439-170FA9A2CEB6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Lo Russo
@ast
Giuseppe Lo Russo
@en
Giuseppe Lo Russo
@es
Giuseppe Lo Russo
@nl
Giuseppe Lo Russo
@sl
type
label
Giuseppe Lo Russo
@ast
Giuseppe Lo Russo
@en
Giuseppe Lo Russo
@es
Giuseppe Lo Russo
@nl
Giuseppe Lo Russo
@sl
prefLabel
Giuseppe Lo Russo
@ast
Giuseppe Lo Russo
@en
Giuseppe Lo Russo
@es
Giuseppe Lo Russo
@nl
Giuseppe Lo Russo
@sl
P1053
D-5586-2017
P106
P1153
37761706300
P21
P31
P3829
P496
0000-0003-3224-2728